What CMS launched
CMS says ACCESS began July 5, 2026, and is scheduled to run through June 30, 2036. The voluntary model tests recurring Outcome-Aligned Payments to Medicare Part B-enrolled care organizations in four tracks: early cardio-kidney-metabolic conditions; diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease; chronic musculoskeletal pain; and depression or anxiety. Eligible patients must have Original Medicare Parts A and B with Medicare as the primary payer; Medicare Advantage, PACE, and hospice enrollment are among the exclusions.
Medication management is one example of care an ACCESS organization may provide, alongside monitoring, care coordination, and clinician consultation. CMS ties full payment to measurable outcomes assessed across the participant's patient panel. That does not create a universal pharmacy-service code, establish that every pharmacy qualifies, or show how a downstream pharmacy will be paid.
Read GamePlan's public status precisely
CMS updated its accepted-applicant page on July 20. It lists GamePlan Medical for all four clinical tracks. CMS also warns that inclusion is not an endorsement and does not guarantee participation; Medicare enrollment, execution of a Participation Agreement, and final CMS approval remain conditions.
NCPA's July 21 notice describes ACCESS to Pharmacy Care as an NCPA program powered by CPESN USA in partnership with GamePlan. The program site says GamePlan provides medical direction and works with community pharmacies. NCPA calls GamePlan a CMS participant, but the current public CMS page supports the narrower description “accepted applicant.” A pharmacy should confirm current CMS status and the named contracting entity before relying on either label.
Treat $8–$10 as a program claim, not a CMS rate
NCPA says participation creates “opportunities for increased revenue” of $8–$10 per patient per month and “has no cost to participate.” That is the strongest supportable wording. The reviewed CMS pages do not set an $8–$10 pharmacy rate: CMS describes payments to ACCESS participants, while NCPA describes a pathway through GamePlan for community pharmacies.
That distinction matters because CMS's Request for Applications withholds later participant installments and reconciles payment after the care period using clinical-outcome and substitute-spend adjustments. The public program pages reviewed do not say how those participant-level adjustments flow through to a pharmacy. Nor does “no cost to participate” establish zero total cost. The program site says participation is open to NCPA members and CPESN participating pharmacies; a buyer should ask whether membership, staffing, devices, training, documentation, or software create costs outside the program fee.
A separate pharmacist billing route remains unfinished
CMS also offers a separate Co-Management Payment for reviewing ACCESS care updates and performing related coordination. Its June 5 guidance lists practitioner types eligible to bill beginning July 5, then separately says pharmacists and medical supply companies with pharmacists “will also be eligible” but that billing guidance is forthcoming. Do not present the current $30 co-management codes as generally billable by pharmacists, and do not equate NCPA's $8–$10 claim with the Co-Management Payment.
If CMS later publishes pharmacist guidance, check its effective date, enrollment type, billing entity, required time and documentation, payment frequency, and overlap rules. Until then, the official materials reviewed do not support saying that CMS directly pays a pharmacist $8–$10 monthly through ACCESS.
Ask eight questions before enrolling
- Who is the contractual counterparty, and has the named ACCESS applicant completed CMS approval and its Participation Agreement?
- Does the legal entity qualify through its pharmacy NPI, affiliations, licenses, and state scope, or is an individual pharmacist or consulting-only practice outside the current pathway?
- Who identifies eligible Original Medicare patients, checks exclusions, documents voluntary consent, and handles switching or disenrollment?
- Which interventions, measurements, follow-up, and escalation work must the pharmacy perform, and which remain with GamePlan or another participant?
- Who collects source-verifiable baseline and follow-up measures, submits data to CMS, retains audit evidence, and fixes rejected records?
- How will care plans, medication changes, and urgent findings reach the patient's existing clinicians without duplicating another paid service?
- What exactly triggers the $8–$10 amount, when is it paid, and can performance adjustments, ineligibility, missing data, or early disenrollment reduce or reverse it?
- What happens at termination: who owns the care record, who completes active care periods, and in what usable format can the pharmacy export its data?
Decide whether the pathway fits this practice
The current pathway is aimed at community pharmacies. Its interest form asks for a pharmacy NPI-explicitly not a pharmacist NPI-plus the pharmacy-management system and NCPA or CPESN affiliation. That makes the development relevant to independent consultant pharmacists working in or with a dispensing pharmacy, but the public materials do not establish that a facility-only medication-regimen-review practice can enroll.
ACCESS is a new test, not a completed outcomes study. CMS describes the model's goals, while NCPA makes first-party claims about improved outcomes, coordination, and costs. The reviewed sources do not yet report ACCESS results. For now, the useful story is contract and workflow readiness: trace who is responsible, who reports, who carries the adjustment, and who is paid before rebuilding a service line around the headline number.